Wednesday, November 18, 2026
David Carrasco
- The genetic make-up of the Meso- American population (Central America and Mexico) will be known by the year 2005, as the result of a scientific project that is exploring new strategies to combat congenital diseases in the region.
Tomas Arias, the project’s coordinator, told IPS that the initiative, in which all principal Central American research institutes are participating, aims to clarify the various influences on the genetic structure of people in the region and the effect of drugs and other chemical agents used in medicine.
Arias, the president of the Institute of DNA and the Human Genome (Ingen) of the University of Panama, indicated that the research aspires to open new horizons in the approach to emerging infectious diseases and those that result from genetic and environmental imbalances.
He emphasised there were gaps in this field of research because pharmaceutical companies in developed countries – with the exception of Japan – designed treatment based primarily on research conducted within white populations, their principal market.
He added that the drugs and therapies used in wealthy countries were not effective or had a different result in developing countries, where there was greater genetic diversity within the population.
“That is what we hope to determine through the DNA (deoxyribonucleic acid) markers obtained from representative populations of the region,” Arias said, explaining the scope of the collaborative effort by area universities.
Scientific interest in DNA is based on the fact that it provides the blueprint for reproduction and cellular function, and represents a “back-up” of the primary genetic information of all living beings.
Lucia Jorge, a member of the Ingen research team, noted that the project used methods that differed from traditional techniques in taking a look at the various human genotypes in Latin America.
This year, the initiative received the backing of the Association of Universities and Institutions of Higher Education of Mexico and the Higher Council of Universities of Central America in securing advanced levels of research and academic exchange.
Arias said that the human genome study (the set of chromosomes of a nucleus, cell or individual), in which Panama is a pioneer in the region, was necessary to create a bio-medical system capable of identifying the risk factors associated with genetic inheritance.
The most common congenital diseases in Central America included sickle cell anemia, whose incidence was higher among black people, diabetes, which affected mostly indigenous communities and cardiovascular disorders, which predominated among those of European descent.
A genetic study performed by Ingen in Panama surprisingly revealed that the population of this country, which is mostly white-skinned, carried 36 percent indigenous genes, 34 percent African genes and 30 percent white or caucasian genes.
According to statistics, indigenous people represented only nine percent of the 2.8 million inhabitants of Panama but the dominant presence of their genes in the blood of Panamanians, indicated that they were not the “minority” previously believed.
Atencio Lopez, a leader of the indigenous Kuna community and the current representative of Panama to the Central American Parliament, told IPS that the Ingen report confirmed the historic fact that “aboriginal cultures have contributed to forging the Panamanian nationality and unity.”
Lopez said that, despite ignorance or denial of that truth, many people were being forced to recognise it thanks to irrefutable scientific evidence that the heritage and culture of indigenous peoples was more alive than ever.
However, he added that genetic research should be carried out within a strict ethical framework since deviations could lead to unforeseen consequences, such as a market in the patenting of genes for profit or racial selection.
At the start of the decade, indigenous activists in Panama and the United States managed to halt a global project on the human genome that aspired to obtain a commercial patent on the antibodies found in the blood of indigenous Panamanians.
The blood samples were taken illegally by a United States doctor who tried to take advantage of the competition among giant laboratories interested in creating a vaccine against HIV, the virus that causes the acquired immune deficiency syndrome (AIDS).
The project folded due to pressure from activists, but left doubts over the unscrupulous practices of some countries in the industrialised North which attempt to make a profit on human groups they consider “guinea pigs.”
Notwithstanding, Arias denied that the university project he heads has any relationship with the failed United States initiative, which he rejects as having lacked standards and ethical principles.
The president of Ingen recognised that the search for patents on genes, molecules or drugs derived from human genetic material is a source of international debate, particularly when it does not take into account the rights of communities or populations which contribute genetic material.
He added that new discoveries and advances in the genome study will be shared with other countries in the region and their research institutes, to help cement scientific collaboration for the benefit of humanity.
In that respect, Arias underlined that the first symposium on the biomedicine of the populations of Panama and its borders will take place from Dec. 2 to 4 in the Panama’s capital, with the participation of scientists from Central America, Canada and the United States, as well as the World Health Organisation.
Biochemists, geneticists, toxicologists and other biological research professionals will meet to study the interaction of genetic structure and the environment, as well as the effects of different drugs on the population.
The symposium will focus on recent advances in DNA research and their applications in the diagnosis and treatment of disease.
Arias believes it is just the first step down a long road, which is delving into humanity’s past in search of answers to persistent questions in the fields of anthropology and human health.